TY - JOUR
T1 - Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer
T2 - implications for better risk stratification and preoperative prediction of oncologic outcomes
AU - Choi, Seung Kwon
AU - Shim, Myungsun
AU - Kim, Myong
AU - Park, Myungchan
AU - Lee, Sangmi
AU - Song, Cheryn
AU - Lee, Hyung Lae
AU - Ahn, Hanjong
N1 - Publisher Copyright:
© 2017, Springer-Verlag Berlin Heidelberg.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Purpose: To evaluate the better risk stratification based on surgical pathology, and to predict oncologic outcomes after radical prostatectomy (RP) with a better scoring system in high-risk prostate cancer (PCa) patients. Methods: We evaluated high-risk PCa patients (PSA >20 ng/ml, ≥cT3a, or Gleason score 8–10) who underwent RP between 2007 and 2013 at our institute. We classified patients into three groups according to their pathologic outcomes: favorable (pT2, Gleason score ≤7, and node negative), intermediate (specimen-confined disease (pT2-3a, node negative PCa with negative surgical margins) but not in the favorable group), and unfavorable (the remaining patients). We developed a risk stratification scoring system to predict prognostic outcomes after RP and validated our scoring system to estimate its predictive accuracy. Results: Among a total of 356 patients, 95 (26.7%), 115 (32.3%), and 146 (41%) were in the favorable, intermediate, and unfavorable prognostic groups, respectively. The 5-year biochemical recurrence-free survival rates of the patients in each group were 87.8, 64.6, and 41.4%, respectively. We developed a scoring system based on preoperative PSA, clinical stage, percentage of tumor positive core, and percentage of cores with a Gleason score 8–10. This demonstrated internally and externally validated concordance indices of 0.733 and 0.772, respectively. Conclusions: Using our scoring system, we can predict which patients with high-risk PCa would benefit more from RP. Thus, this system can be used in patient counseling to determine an optimal treatment strategy for high-risk PCa.
AB - Purpose: To evaluate the better risk stratification based on surgical pathology, and to predict oncologic outcomes after radical prostatectomy (RP) with a better scoring system in high-risk prostate cancer (PCa) patients. Methods: We evaluated high-risk PCa patients (PSA >20 ng/ml, ≥cT3a, or Gleason score 8–10) who underwent RP between 2007 and 2013 at our institute. We classified patients into three groups according to their pathologic outcomes: favorable (pT2, Gleason score ≤7, and node negative), intermediate (specimen-confined disease (pT2-3a, node negative PCa with negative surgical margins) but not in the favorable group), and unfavorable (the remaining patients). We developed a risk stratification scoring system to predict prognostic outcomes after RP and validated our scoring system to estimate its predictive accuracy. Results: Among a total of 356 patients, 95 (26.7%), 115 (32.3%), and 146 (41%) were in the favorable, intermediate, and unfavorable prognostic groups, respectively. The 5-year biochemical recurrence-free survival rates of the patients in each group were 87.8, 64.6, and 41.4%, respectively. We developed a scoring system based on preoperative PSA, clinical stage, percentage of tumor positive core, and percentage of cores with a Gleason score 8–10. This demonstrated internally and externally validated concordance indices of 0.733 and 0.772, respectively. Conclusions: Using our scoring system, we can predict which patients with high-risk PCa would benefit more from RP. Thus, this system can be used in patient counseling to determine an optimal treatment strategy for high-risk PCa.
KW - Models
KW - Prognosis
KW - Prostatectomy
KW - Prostatic neoplasms
KW - Risk
KW - Risk assessment
KW - Statistical
UR - http://www.scopus.com/inward/record.url?scp=85019766460&partnerID=8YFLogxK
U2 - 10.1007/s00432-017-2437-z
DO - 10.1007/s00432-017-2437-z
M3 - Article
C2 - 28523407
AN - SCOPUS:85019766460
SN - 0171-5216
VL - 143
SP - 1871
EP - 1878
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 9
ER -